183 related articles for article (PubMed ID: 36905528)
1. Assessing the Impact of Immunogenicity and Improving Prediction of Trough Concentrations: Population Pharmacokinetic Modeling of Adalimumab in Patients with Crohn's Disease and Ulcerative Colitis.
Ponce-Bobadilla AV; Stodtmann S; Chen MJ; Winzenborg I; Mensing S; Blaes J; Haslberger T; Laplanche L; Dreher I; Mostafa NM
Clin Pharmacokinet; 2023 Apr; 62(4):623-634. PubMed ID: 36905528
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the ELISA and ECL Assay for Vedolizumab Anti-drug Antibodies: Assessing the Impact on Pharmacokinetics and Safety Outcomes of the Phase 3 GEMINI Trials.
Wyant T; Yang L; Rosario M
AAPS J; 2020 Nov; 23(1):3. PubMed ID: 33200296
[TBL] [Abstract][Full Text] [Related]
3. Baseline TREM-1 Whole Blood Gene Expression Does Not Predict Response to Adalimumab Treatment in Patients with Ulcerative Colitis or Crohn's Disease in the SERENE Studies.
Verstockt B; Pivorunas V; Al Mahi N; Smaoui N; Guay H; Kennedy NA; Goodhand JR; Lin S; Bai BYH; Hanauer SB; Ferrante M; Panés J; Vermeire S
J Crohns Colitis; 2024 Apr; 18(4):493-505. PubMed ID: 37801628
[TBL] [Abstract][Full Text] [Related]
4. Infliximab and adalimumab concentrations and anti-drug antibodies in inflammatory bowel disease control using New Zealand assays.
Barclay ML; Karim S; Helms ETJ; Keating PE; Hock B; Stamp LK; Schultz M
Intern Med J; 2019 Apr; 49(4):513-518. PubMed ID: 30091273
[TBL] [Abstract][Full Text] [Related]
5. Population Pharmacokinetics and Pharmacodynamics of Ontamalimab (SHP647), a Fully Human Monoclonal Antibody Against Mucosal Addressin Cell Adhesion Molecule-1 (MAdCAM-1), in Patients With Ulcerative Colitis or Crohn's Disease.
Wang Y; Marier JF; Lavigne J; Kassir N; Martin P
J Clin Pharmacol; 2020 Jul; 60(7):903-914. PubMed ID: 32119128
[TBL] [Abstract][Full Text] [Related]
6. Clinical utility of newly developed immunoassays for serum concentrations of adalimumab and anti-adalimumab antibodies in patients with Crohn's disease.
Imaeda H; Takahashi K; Fujimoto T; Bamba S; Tsujikawa T; Sasaki M; Fujiyama Y; Andoh A
J Gastroenterol; 2014 Jan; 49(1):100-9. PubMed ID: 23575576
[TBL] [Abstract][Full Text] [Related]
7. Higher Adalimumab Levels Are Associated with Histologic and Endoscopic Remission in Patients with Crohn's Disease and Ulcerative Colitis.
Yarur AJ; Jain A; Hauenstein SI; Quintero MA; Barkin JS; Deshpande AR; Sussman DA; Singh S; Abreu MT
Inflamm Bowel Dis; 2016 Feb; 22(2):409-15. PubMed ID: 26752470
[TBL] [Abstract][Full Text] [Related]
8. Prospective Observational Evaluation of the Time-Dependency of Adalimumab Immunogenicity and Drug Concentration in Ulcerative Colitis Patients: the POETIC II Study.
Harnik S; Abitbol CM; Haj Natour O; Yavzori M; Fudim E; Picard O; Naftali T; Broide E; Hirsch A; Selinger L; Shachar E; Yablecovitch D; Albshesh A; Coscas D; Kopylov U; Eliakim R; Ben-Horin S; Ungar B
J Crohns Colitis; 2024 Mar; 18(3):341-348. PubMed ID: 37691574
[TBL] [Abstract][Full Text] [Related]
9. Adalimumab Clearance, Rather Than Trough Level, May Have Greatest Relevance to Crohn's Disease Therapeutic Outcomes Assessed Clinically and Endoscopically.
Wright EK; Chaparro M; Gionchetti P; Hamilton AL; Schulberg J; Gisbert JP; Chiara Valerii M; Rizzello F; De Cruz P; Panetta JC; Everts-van der Wind A; Kamm MA; Dervieux T
J Crohns Colitis; 2024 Feb; 18(2):212-222. PubMed ID: 37594369
[TBL] [Abstract][Full Text] [Related]
10. Leucine-Rich Alpha-2 Glycoprotein May Be Predictive of the Adalimumab Trough Level and Antidrug Antibody Development for Patients with Inflammatory Bowel Disease: A Sub-Analysis of the PLANET Study.
Yanai S; Shinzaki S; Matsuoka K; Mizuno S; Iijima H; Naka T; Kanai T; Matsumoto T
Digestion; 2021; 102(6):929-937. PubMed ID: 34350873
[TBL] [Abstract][Full Text] [Related]
11. Association between serum adalimumab concentrations and endoscopic disease activity in patients with Crohn's disease.
Morita Y; Imaeda H; Nishida A; Inatomi O; Bamba S; Sasaki M; Tsujikawa T; Sugimoto M; Andoh A
J Gastroenterol Hepatol; 2016 Nov; 31(11):1831-1836. PubMed ID: 27043158
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease.
Rosario M; Dirks NL; Gastonguay MR; Fasanmade AA; Wyant T; Parikh A; Sandborn WJ; Feagan BG; Reinisch W; Fox I
Aliment Pharmacol Ther; 2015 Jul; 42(2):188-202. PubMed ID: 25996351
[TBL] [Abstract][Full Text] [Related]
13. Population Pharmacokinetics and Exposure-Response Analyses of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease.
Adedokun OJ; Xu Z; Gasink C; Kowalski K; Sandborn WJ; Feagan B
Clin Ther; 2022 Oct; 44(10):1336-1355. PubMed ID: 36150926
[TBL] [Abstract][Full Text] [Related]
14. Assessing adherence to objective disease monitoring and outcomes with adalimumab in a real-world IBD cohort.
Al Khoury A; Xiao Y; Golovics PA; Kohen R; Afif W; Wild G; Friedman G; Galiatsatos P; Hilzenrat N; Szilagyi A; Wyse J; Cohen A; Bitton A; Bessissow T; Lakatos PL
Dig Liver Dis; 2021 Aug; 53(8):980-986. PubMed ID: 33640302
[TBL] [Abstract][Full Text] [Related]
15. INFLIXIMAB AND ADALIMUMAB SERUM TROUGH CONCENTRATIONS THRESHOLD ASSOCIATED WITH DEEP REMISSION IN INFLAMMATORY BOWEL DISEASE.
Pascual-Marmaneu Ó; Belles-Medall MD; Ferrando-Piqueres R; Almela-Notari P; Mendoza-Aguilera M; Álvarez-Martín T
Farm Hosp; 2021 Aug; 45(5):225-233. PubMed ID: 34806581
[TBL] [Abstract][Full Text] [Related]
16. Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventional therapy.
Colombel JF; Jharap B; Sandborn WJ; Feagan B; Peyrin-Biroulet L; Eichner SF; Robinson AM; Mostafa NM; Zhou Q; Thakkar RB
Aliment Pharmacol Ther; 2017 Jan; 45(1):50-62. PubMed ID: 27883215
[TBL] [Abstract][Full Text] [Related]
17. Swapping Versus Dose Optimization in Patients Losing Response to Adalimumab With Adequate Drug Levels.
Roblin X; Genin C; Nancey S; Williet N; Veyrard P; Boschetti G; Phelip JM; Berger AE; Killian M; Waeckel L; Flourie B; Paul S
Inflamm Bowel Dis; 2022 May; 28(5):720-727. PubMed ID: 34405867
[TBL] [Abstract][Full Text] [Related]
18. Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases.
Roblin X; Marotte H; Rinaudo M; Del Tedesco E; Moreau A; Phelip JM; Genin C; Peyrin-Biroulet L; Paul S
Clin Gastroenterol Hepatol; 2014 Jan; 12(1):80-84.e2. PubMed ID: 23891927
[TBL] [Abstract][Full Text] [Related]
19. Vedolizumab Efficacy, Safety, and Pharmacokinetics With Reduced Frequency of Dosing From Every 4 Weeks to Every 8 Weeks in Patients With Crohn's Disease or Ulcerative Colitis.
Vermeire S; Lukáš M; Magro F; Adsul S; Lindner D; Rosario M; Roth J; Danese S
J Crohns Colitis; 2020 Sep; 14(8):1066-1073. PubMed ID: 32060515
[TBL] [Abstract][Full Text] [Related]
20. Subcutaneous Absorption Contributes to Observed Interindividual Variability in Adalimumab Serum Concentrations in Crohn's Disease: A Prospective Multicentre Study.
Vande Casteele N; Baert F; Bian S; Dreesen E; Compernolle G; Van Assche G; Ferrante M; Vermeire S; Gils A
J Crohns Colitis; 2019 Sep; 13(10):1248-1256. PubMed ID: 30820530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
